ROCKLAND, Mass. — EMD Serono, the Healthcare business of Merck KGaA in the U.S. and Canada, today announced new real-world data that continue to reinforce the JAVELIN Bladder regimen of first-line platinum-based chemotherapy followed by BAVENCIO® (avelumab) maintenance as a standard of care for eligible patients with locally advanced or...
Latest News
Aurora, Colorado – New research overseen by University of Colorado Cancer Center member Rebecca Schweppe, PhD, could lead to improved treatment for people with thyroid cancer characterized by a mutation in the BRAF gene, a mutation also responsible for some types of melanoma, colorectal cancer, leukemia, lymphoma, and ovarian cancer....
Melbourne, Australia – In the study led by the Peter Doherty Institute for Infection and Immunity (Doherty Institute) and published in Science Immunology, the researchers found that CD4+ T cells, traditionally called ‘helper T cells’ for their role in aiding the activation of other immune cells, are remarkably effective in...
Leawood, Kansas – Researchers performed a meta-analysis of randomized trial studies that compared the use of amyloid-reducing monoclonal antibodies (MABs) in patients with Alzheimer dementia at a dose consistent with that used in Phase 3 or FDA approval trials with the use of a placebo. Their purpose was to evaluate...
Montreal, Canada – A common stomach bacteria found in two thirds of the world population may be linked to a higher risk of Alzheimer’s disease, new research suggests. The study, published in Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association, investigated whether a clinically apparent Helicobacter pylori (H. pylori)...
BUFFALO, NY – A new review was published in Oncotarget’s Volume 15 on August 2, 2024, entitled, “Targeting WNT5B and WNT10B in osteosarcoma.” As noted in the abstract of this paper, WNT signaling regulates osteosarcoma proliferation. There is, however, controversy in the field of osteosarcoma as to whether WNT signaling...
Cellular immunotherapies have so far not been very effective against non-Hodgkin’s lymphoma. A team led by Armin Rehm of the MDC has discovered a possible reason. As the they describe in “Cell Reports”, this cancer induces changes in the large blood vessels through which immune cells normally migrate to the lymph...
SHANGHAI, China — Dizal (SSE:688192), a biopharmaceutical company committed to developing novel medicines for the treatment of cancer and immunological diseases, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to its Birelentinib (DZD8586) for the treatment of adult patients with relapsed/refractory chronic lymphocytic leukemia or small...
PRINCETON, N.J. – Bristol Myers Squibb (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) approved Opdivo® (nivolumab), in combination with cisplatin and gemcitabine, for the first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC), the most common type of bladder cancer. This approval...
A disease registry may serve as a more suitable data source for evaluation of factor VIII inhibitors in pediatric patients receiving orphan drug treatment for hemophilia A compared with a single-arm clinical trial. While several new factor VIII products have been developed in recent years, the rarity of hemophilia A...